Navigation Links
Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
Date:11/6/2013

SAN DIEGO, Nov. 6, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that it has entered into a commercial supply agreement with Sanofi to act as Orexigen's contract manufacturer for Contrave® (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for territories outside North America.  Sanofi will manufacture Contrave tablets at one of several facilities in France.

"We are pleased to engage a manufacturer with Sanofi's scale and expertise," said Michael Narachi, CEO of Orexigen. "This agreement expands and diversifies our existing commercial supply network and will help ensure we will be ready to supply Contrave globally if approved."

About Contrave
Orexigen is evaluating Contrave for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with lifestyle modification, and is currently conducting the Light Study, a cardiovascular outcomes trial. The primary objective of the double‐blind, randomized, placebo‐controlled clinical trial, which Orexigen is conducting under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis of the Light Study is anticipated by early December, enabling the potential resubmission of the Contrave New Drug Application (NDA) to the FDA by year end.

In October Orexigen submitted a Marketing Authorization Application (MAA) for Contrave to the European Medicines Agency (EMA).

Orexigen has licensed North American Contrave commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights in Europe and
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
2. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
3. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
4. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
5. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
6. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
7. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
8. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
9. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
10. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 ... healthcare funding changes brought about by the ... both reimbursement and prescribing of pharmaceutical therapies. ... (MCOs) cover beneficiaries through new regulations and ... is occurring in the health exchanges—state-based marketplaces ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
(Date:7/31/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... BIIB - Free Report ), Gilead (Nasdaq: GILD ... Free Report ), AbbVie (NYSE: ABBV - Free Report ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... SHAWNEE, Kan., June 17, 2011 Bayer HealthCare LLC ... of the lawsuit between Bayer and Farnam Companies Inc. ... tick control products.  As part of the settlement, Farnam ... Farnam,s print and online advertising campaign included claims that ...
... 17, 2011 NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank, CEO, received the ... 2011 New England Award in the Medical Devices category. ... extraordinary success in such areas as innovation, financial performance ...
Cached Medicine Technology:Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads 2NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 2NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 3NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 4
(Date:7/31/2014)... Cosmetic Town has introduced a secure verification ... will be able to verify their patients before the ... guarantees their authenticity. This will help prospective patients ... information that has been verified to come from a ... Town to filter out fake patients who leave fraudulent ...
(Date:7/31/2014)... 2014 NEWwoodworks, fine woodworking group at ... brand presence with a website dedicated to highlighting their ... has specialized in handcrafted cabinetry, furniture, stairs , ... earned a reputation for taking on the remarkable, challenging ... commonly craft with reclaimed wood, often using near extinct ...
(Date:7/31/2014)... July 31, 2014 US Hair Restoration Founder, ... now be known as Parsa Mohebi Hair Restoration. Since ... of patients in Southern California and around the world, who ... Hills and Orange County. These patients achieved the full benefits ... techniques that were perfected by Dr. Mohebi. They have ...
(Date:7/31/2014)... Daily Gossip indicates in its "Neuropathy Miracle" review ... problem. However, this is not a solution. , The ... Peter Bansby, who decided to reveal his method with ... world find a unique way of overcoming their health ... and cons from a full Neuropathy Miracle review, simply ...
(Date:7/31/2014)... 31, 2014 July 31, 2014- Title Boxing ... celebrate they have launched a Facebook Sweepstakes giving away prizes ... you have to do is visit http://www.facebook.com/titleboxingcoolsprings and ... share with your friends, and for each one that enters, ... “We are so excited to bring such a new and ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2
... , , WEDNESDAY, May 28 (HealthDay News) -- Two new ... , Almost 15 percent of Americans are constipated at any ... of two reports in the May 29 issue of the ... on the efficacy of the experimental drug prucalopride on 620 ...
... N.Y., May 28 Caribbean People,International Collective Inc (CPIC) ... community event is set for Sunday, June 8th 2008--Caribbean,American ... opening,sunrise ceremony at 9:30 A.M. and then will kick ... at 10:15 A.M. The 5 K Walk will,continue throughout ...
... Sanaa Lathan Celebrates Inspirational Stories of how People ... ENGLEWOOD CLIFFS, N.J., May 28 Skin is,amazing: it covers ... a,symbol of pride, for others it,s a canvas to tell ... to be honored. Skin means something different,to almost everyone you ...
... ANGELES, May 28 Dr. Jeffrey Cummings, Medical,Director ... at UCLA,received the prestigious Ronald and Nancy Reagan ... team devote themselves to, discovering new,treatments and methods ... disorders., In his speech of acceptance at ...
... a world of internet savvy,patients and consumers, everyday tasks ... With a few clicks of the mouse, your patient,can ... even buy,groceries! A patient,s experience with their dentist is ... friendly., With the new Smile Dash Patient Portal ...
... It could mean development of new class of drugs, ... new compound that inhibits HIV protease has been developed by ... which is necessary for HIV replication, is a common target ... first new HIV protease inhibitor compound to be developed in ...
Cached Medicine News:Health News:Two Drugs Show Promise Against Severe Constipation 2Health News:Two Drugs Show Promise Against Severe Constipation 3Health News:Caribbean People International Collective Inc to Host 8th Annual AIDS WALK CARIBBEAN 2Health News:Vaseline(R) Cocoa Butter Campaign Uncovers Skin's Ability to Speak Volumes 2Health News:Vaseline(R) Cocoa Butter Campaign Uncovers Skin's Ability to Speak Volumes 3Health News:Vaseline(R) Cocoa Butter Campaign Uncovers Skin's Ability to Speak Volumes 4Health News:Empowering Your Patients: Smile Dash Portal 'Bridges Gap' Between Dentists and Patients 2Health News:New Compound Slows HIV Replication 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: